Bedfont announces launch of 2nd generation NObreath® at ERS 2018, Paris

Bedfont Scientific Ltd. launches their new and improved FeNO monitor exclusively at the world’s largest European Respiratory Society Congress with a competition to win one.

Medical device manufacturer, Bedfont, who have specialised in breath analysis for over 40 years, have announced a new and improved 2nd generation NObreath®. The FeNO monitor will be launched exclusively at ERS, the world’s largest European Respiratory Society Congress, which takes place this year September 15-19th in Paris.

The 2nd generation FeNO monitor is launched after the recent publication of the NICE guidance on Asthma: diagnosis, monitoring and chronic asthma management, to improve asthma care, which included the NObreath® FeNO monitor from Bedfont as a recommended device[1,2].

To celebrate the exclusive launch, the second-generation family business will also be holding a competition at their stand where delegates will have the chance to be entered into a prize draw to win a new NObreath®.

Jason Smith, Managing Director, comments, “As a breath analysis medical device manufacturer who exports globally, ERS is a key congress for us to reconnect with our customers from around the world. We are thrilled to be launching the 2nd generation NObreath® exclusively at ERS this year as we feel it would be quite symbolic; this launch will bring the product full circle, as the very first NObreath® was too launched at an ERS Congress 11 years ago. We’re excited to show our customers what’s in store for the advancement of respiratory care.” 


1.     Asthma: diagnosis, monitoring and chronic asthma management | Guidance and guidelines | NICE [Internet]. 2018 [cited 24 April 2018]. Available from:

2.     Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | Guidance and guidelines | NICE [Internet]. 2014 [cited 24 April 2018]. Available from: